Wide discrepancies in activated clotting times measured by two devices were detected for a patient with lupus anticoagulant in a cardiac surgery.
Perfusion
; 31(8): 709-710, 2016 Nov.
Article
em En
| MEDLINE
| ID: mdl-27758970
ABSTRACT
INTRODUCTION:
For a patient with lupus anticoagulant (LA), activated coagulation time (ACT) was measured with two different types of devices (HEMOCHRON® 801 and HEMOCHRON® Jr). CASE REPORT ACTs during heparinization measured with the HEMOCHRON® 801 were over the range of measurement, while those with the HEMOCHRON® Jr. reflected an almost normal response to heparin.DISCUSSION:
The phospholipid contained in an activating agent of the HEMOCHRON® Jr was suggested to have counteracted the effect of LA.CONCLUSION:
It was indicated that the coagulation status for LA-positive patients might be better assessed by ACT measured with phospholipid in an activating agent, although careful interpretation is required.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
Perfusion
Ano de publicação:
2016
Tipo de documento:
Article